Galderma’s Nemolizumab Approved for AD and PN in the UK and Switzerland
Just days after snagging dual approvals for moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the European Union, nemolizumab (Nemluvio, Galderma) was also granted Marketing Authorization in the United Kingdom (UK) and Switzerland for AD and PN. The UK Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab […]